Xianfu Wu – Pharmaceutical Analysis Award – Best Researcher Award

Xianfu Wu – Pharmaceutical Analysis Award – Best Researcher Award

Prof Dr. Xianfu Wu distinguished academic and researcher in the field Pharmaceutical Analysis.  Xianfu Wu was graduated with his Ph.D degree of medicinal chemistry from Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College (PUMC) in 2009. Then he joined the faculty at Institute of Microbiology, Chinese Academy of Sciences as associate professor. In 2012, He moved to National Institutes for Food and Drug Control of National Medical Products Administration (NMPA). Dr. Wu’s research interest is mainly focused on the studying on drug quality control and drug reference standards

🌐 Professional Profiles

Educations📚📚📚

He pursued his academic journey with a keen focus on medicinal chemistry, culminating in a Ph.D. from the Institute of Materia Medica at the Chinese Academy of Medical Sciences & Peking Union Medical College in 2009. Prior to his doctoral studies, he completed a Master’s degree in Medicinal Chemistry at Shenyang Pharmaceutical University in 2006, building upon his foundational education in the Science of Chinese Materia Medica, which he obtained from Hubei University of Chinese Medicine in 2003. Throughout his educational endeavors, he demonstrated a deep-seated commitment to advancing his expertise in the field of medicinal chemistry, laying a solid groundwork for his future endeavors in pharmaceutical research and development.

 Work experiences

He assumed various roles within the academic and research spheres, showcasing his expertise and leadership capabilities. Since June 2012, he has served as a Professor, Master’s Supervisor, and Director of the Department at the National Institutes for Food and Drug Control under the National Medical Products Administration (NMPA) in China. In this capacity, he has been instrumental in guiding research initiatives and overseeing the regulatory aspects of food and drug control in the country. Prior to this, from August 2009 to June 2012, he held the position of Research Associate at the Institute of Microbiology within the Chinese Academy of Sciences, contributing to advancements in microbiological research and fostering collaborations within the scientific community. Throughout his career, he has consistently demonstrated a dedication to excellence and a passion for furthering scientific knowledge and regulatory standards in his field.

Research Directions

He has been actively engaged in diverse research areas, showcasing his versatility and breadth of expertise. His investigations encompass a wide array of topics, including the exploration of new technologies and methodologies for enhancing drug quality control, reflecting his commitment to staying at the forefront of scientific advancements. Furthermore, his research delves into the application of nuclear magnetic resonance spectroscopy within complex drug systems, highlighting his proficiency in utilizing advanced analytical techniques to elucidate molecular structures and dynamics. Additionally, he has contributed significantly to the field of drug quality control through his studies, demonstrating a meticulous approach to ensuring the safety and efficacy of pharmaceutical products. Moreover, his investigations into the bioactive substances and functional properties of natural medicines underscore his interest in harnessing the therapeutic potential of natural compounds for medicinal purposes. Through his multifaceted research endeavors, he continues to make significant strides in advancing our understanding of pharmaceutical science and its applications in healthcare.

Grants & Research Projects

He has secured several prestigious grants and research projects, showcasing his leadership in securing funding and his dedication to advancing scientific knowledge. Among these projects is the National Natural Science Foundation of China-funded research on the “Antitumor activity of benzophenone derived from endophytic fungi of the genus Pestalotiopsis” (Project No.: 81102338), highlighting his focus on exploring natural compounds for potential therapeutic applications. Additionally, he has led initiatives supported by the Technology Foundation of the General Administration of Quality Supervision, Inspection, and Quarantine of China, such as the project addressing the urgent need for “Chemical reference materials in safety testing of cosmetics in China” (Project No.: 2012104008), demonstrating his commitment to regulatory standards and consumer safety. Moreover, his involvement in projects aimed at improving the standards of the Chinese Pharmacopoeia Committee, including the identification of low molecular weight heparin series products by nuclear magnetic resonance spectrum (Project No.: 443) and the study on the determination technique of water-solid interaction in drug systems (Project No.: 2019Y16), underscores his expertise in pharmaceutical quality control and analytical techniques. Through his leadership and involvement in these projects, he continues to make significant contributions to the advancement of pharmaceutical science and regulatory standards in China.

Achievements

His achievements exemplify a distinguished career marked by significant contributions to pharmaceutical science and regulatory standards. Notably, he played a pivotal role in drafting Chinese Pharmacopoeia standards for nuclear magnetic resonance identification of three low molecular weight heparin products, namely dalteparin sodium, nadroparin calcium, and enoxaparin sodium, enhancing the quality control of these crucial pharmaceuticals. Furthermore, his research on the dynamic vapor adsorption method in pharmaceuticals and reference standards has laid a solid groundwork for its application and dissemination within the industry. His systematic exploration of nuclear magnetic resonance spectroscopy has yielded innovative methods for quantifying drug content, detecting impurities, and controlling residual solvents, thereby revolutionizing drug quality assessment. Additionally, his extensive work in natural product isolation has led to the discovery of over 90 compounds, including more than 30 novel ones, expanding the structural diversity of natural product compounds. Moreover, his leadership in developing over 130 new drug reference standards has provided indispensable support for the advancement of the drug industry and regulatory oversight, further solidifying his reputation as a trailblazer in pharmaceutical research and development.

📝🔬Publications📝🔬